RxDoctor Payments Data

Richard Prince, MD

Ophthalmology · Southampton, PANPI 1164431599

Payments from drug & device makers

$2,005in general payments, 2019–2025

Across 91 payments — averaging $22.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$388
  • Alcon$322
  • Johnson & Johnson Surgical Vision, Inc.$240
  • Novartis$200
  • Sun Pharmaceutical Industries Inc.$173
  • Oyster Point Pharma, Inc.$148
  • plus $534 from 14 others

What the payments were for

  • Food & beverage$1,98899%
  • Gifts$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,005 in reported general payments places this provider in the 55th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$599,163
Medicare patients
1,844
Services billed
5,055

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine28$44,295
LumiganBimatoprost95$41,573
Cyclosporine27$21,459
XiidraLifitegrast17$20,914
Prednisolone Acetate364$12,208
MieboPerfluorohexyloctane/Pf14$9,890
Travoprost44$6,820
Latanoprost608$6,147
Alphagan PBrimonidine Tartrate15$5,371
RocklatanNetarsudil Mesylat/Latanoprost11$5,074
CombiganBrimonidine Tartrate/Timolol15$4,911
MoxifloxacinMoxifloxacin Hcl263$3,939
Ketorolac Tromethamine268$3,456
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat191$3,020
Brimonidine Tartrate61$2,449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$388$96,150153 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$35$30,80431 claims
Aerie Pharmaceuticals, Inc.Rocklatan$15$5,07411 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$61$1,97212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Southampton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →